UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in adults with moderate-to-severe hidradenitis suppurativa (HS).

Calcineurin inhibitors (CNIs) are essential medications for many people living with solid-organ transplants. CNI therapy helps prevent organ transplant rejection, though it requires monitoring to ...